New Citations in March 2026
In March 2026, AntibodySystem products continued to empower cutting-edge multidisciplinary research worldwide. Related findings were published in journals such as Nature Sensors, Phytomedicine, Alzheimer’s Research & Therapy, Virology, and ACS Nano. These studies span critical fields including early cancer diagnostics, bone metabolic diseases, renal fibrosis, neuroimaging, viral vaccines, and tumor immunotherapy, continuously driving innovation at the frontier of science and clinical translation.
Let’s explore some representative publications citing AntibodySystem products in March 2026.
IF 16 ACS Nano
Title: Nanodiamond-Mediated Targeted Delivery of Nanobodies and Immunostimulatory RNA for Breast Cancer Therapy
Core Finding: This study developed a nanodiamond–nanobody–immunostimulatory RNA ternary delivery system. Using the EGFR-specific nanobody 7D12, the system achieves precise targeting of breast cancer cells while co-delivering immunostimulatory RNA to activate innate immunity. This synergistic strategy effectively enhances tumor cell killing and suppresses tumor growth, providing a novel delivery platform for targeted immunotherapy in breast cancer.
Cited Product: RHB86908｜Anti-Human EGFR/ERBB1/HER1 Nanobody (7D12)
Nature Sensors
Title: Oriented nanobody–field-effect transistor interfaces enable ultrasensitive cancer biomarker detection
Core Finding: This study developed a SNAP-FET biosensing platform enabling site-specific anchoring of nanobodies. By integrating genetic code expansion and click chemistry, nanobodies were immobilized in a precisely oriented manner, overcoming Debye screening limitations in serum. The platform achieved attomolar-level detection sensitivity for endometrial cancer biomarkers HE4 and CA125. A portable diagnostic device, ENDOCARE, was also developed, enabling rapid detection within 20 minutes with high consistency to ELISA results and strong diagnostic performance (AUC 0.843 for HE4, 0.813 for CA125).
Cited Products:
EHJ31001｜Recombinant Human MUC16/CA125 Protein, C-His
MVV05491｜Anti-Bacteriophage M13 Capsid Protein G8P Monoclonal Antibody (1A191), HRP
IF 8.3 Phytomedicine
Title: A novel METTL3 inhibitor Nimbolide ameliorates osteoporosis via orchestrating osteoclastogenesis in an m6A-dependent manner
Core Finding: This study demonstrated that METTL3 is significantly upregulated in osteoporosis and promotes osteoclast overactivation via m6A modification of LRP1 mRNA. Nimbolide, a natural compound, was identified as a specific METTL3 inhibitor that directly binds METTL3 and suppresses its methyltransferase activity. This restores LRP1 expression, inhibits osteoclastogenesis, and alleviates osteoporosis in ovariectomized mice without significant toxicity.
Cited Product: YMJ15401｜Recombinant Mouse METTL3 Protein, N-His
IF 8.3 Phytomedicine
Title: Asiaticoside Attenuates Renal Fibrosis by Targeting STAT3 to Restore Th17/Treg Homeostasis
Core Finding: This study identified STAT3 as a key regulator of Th17/Treg imbalance in renal fibrosis. Asiaticoside directly binds to the STAT3 SH2 domain and induces its degradation through an allosteric “binding–destabilization” mechanism. This inhibits STAT3 activation and phosphorylation, reduces pro-inflammatory IL-17A, increases anti-inflammatory IL-10, restores immune balance, and significantly alleviates renal fibrosis and dysfunction.
Cited Products:
EME27701｜Recombinant Mouse STAT3 Protein, C-His
EHE27701｜Recombinant Human STAT3 Protein, C-His
IF 7.6 Alzheimer’s Research & Therapy
Title: In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences
Core Finding: This study demonstrated that the PET tracer florbetaben binds to different sites than therapeutic antibodies lecanemab and donanemab on Aβ plaques. No competitive binding or signal interference was observed, confirming that florbetaben PET can reliably monitor Aβ burden during antibody therapy.
Cited Product: VHC12501｜InVivoMAb Anti-Human APP/Amyloid Beta Antibody (mAb158)
IF 2.4 Virology
Title: Potent protective ability of vaccinia virus LC16 strains lacking the B5R gene
Core Finding: This study engineered a B5R-deficient vaccinia virus strain, demonstrating reduced virulence while retaining strong humoral and cellular immune activation. The strain showed robust protective efficacy in animal models, providing a promising direction for safer vaccine development.
Cited Product: RVV13902｜Anti-Vaccinia Virus (VACV) L1R Protein Antibody (M12B9)
The above highlights represent selected publications citing AntibodySystem products in March 2026. AntibodySystem provides a comprehensive portfolio of research reagents, including recombinant proteins, flow cytometry antibodies, anti-IgE antibodies, phospho-specific antibodies, and ELISA kits, supporting applications in drug target discovery, immunoassays, allergy research, and cancer therapy development.
